Related Experiment Video

Updated: Oct 28, 2025

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

23.2K

Pseudomonas aeruginosa in Bronchiectasis

Laia Fernández-Barat1,2,3, Victoria Alcaraz-Serrano1,2,3, Rosanel Amaro1,2,3

  • 1Cellex Laboratory, CibeRes (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, 06/06/0028), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Seminars in Respiratory and Critical Care Medicine
|July 14, 2021
PubMed

Insights

Pseudomonas aeruginosa (PA) in bronchiectasis (BE) patients worsens outcomes. Understanding PA infections and biofilms in BE is crucial for better diagnosis, treatment, and patient follow-up.

Area of Science:

  • Pulmonary Medicine
  • Infectious Diseases
  • Microbiology

Background:

  • Pseudomonas aeruginosa (PA) presence in bronchiectasis (BE) correlates with poor prognosis and reduced quality of life, indicating disease severity.
  • PA is an opportunistic pathogen adept at forming biofilms and resisting antimicrobial and environmental stresses.
  • Biofilm presence is linked to chronic infection in cystic fibrosis, but its role in BE requires further clarification.

Purpose of the Study:

  • To enhance understanding of Pseudomonas aeruginosa pathophysiology in bronchiectasis.
  • To address inconsistencies in reported infection and eradication rates of PA in BE.
  • To explore the need for revised diagnostic and treatment strategies for PA in BE.

Main Methods:

  • Literature review and synthesis of current research on PA in BE.
  • Analysis of factors contributing to PA persistence and resistance.
  • Evaluation of diagnostic and therapeutic challenges.

Main Results:

  • Inconsistent data exists regarding PA infection, eradication, and chronic infection rates in BE.
  • Inadequate antimicrobial therapy may accelerate progression to chronic infection and antibiotic resistance.
  • The role of PA biofilms in BE pathophysiology is not well-established compared to cystic fibrosis.

Conclusions:

  • A deeper understanding of PA in BE is essential for improving diagnostic accuracy and defining chronic infection.
  • Novel approaches incorporating molecular diagnostics, -omics, and biomarkers are needed to refine patient management.
  • Optimizing treatment strategies is critical to improve eradication rates and patient outcomes in BE.

More Related Videos

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients07:25

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients

Published on: July 16, 2020

3.3K
Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung07:46

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

33.4K

Related Concept Videos

Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
728
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.5K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
433
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
1.3K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
434
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
498